HER2-POSITIVE EARLY BREAST CANCER IN THE PRE-TRASTUZUMAB AND TRASTUZUMAB ERAS: A TRIPLE POSITIVE SUBGROUP ANALYSIS OF A MULTICENTER RETROSPECTIVE STUDY